Nastech Pharmaceutical Company Inc has reacquired all development and commercialization rights for intranasal apomorphine from Pharmacia following the Pfizer-Pharmacia merger pursuant to the terms of the Divestiture Agreement between Nastech and Pharmacia. This reacquisition gives Nastech control of the apomorphine clinical development program for erectile dysfunction and female sexual dysfunction and enables the Company to move the program forward aggressively with a contract research organization (CRO).

"We now have full control of intranasal apomorphine, a promising product that we plan to re-partner under the most favorable of terms," stated Steven C. Quay, Chairman, President, and Chief Executive Officer of Nastech. "In partnership with a CRO, we plan to conduct additional Phase II clinical trials in erectile dysfunction in support of pivotal Phase III studies."

Dr. Quay continued, "The current ED product landscape positions our patented intranasal apomorphine competitively thus enhancing its potential value. To this end, we are currently in discussions with several potential pharmaceutical partners that have the capabilities and resources necessary to conduct all clinical development, including pivotal Phase III trials, obtain the necessary regulatory approvals, and compete effectively in this multi-billion dollar global market."